Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.81 USD | +1.69% | +0.01% | +3.30% |
May. 29 | Transcript : Hologic, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 10:00 AM | |
May. 22 | FDA classifies recall of Hologic's implant as 'most serious' | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- With a 2024 P/E ratio at 22.42 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 4.32 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.30% | 17.23B | B+ | ||
+7.01% | 217B | B | ||
+11.01% | 190B | B- | ||
+19.20% | 143B | B- | ||
+30.79% | 111B | A- | ||
+1.48% | 64.59B | A- | ||
+13.95% | 52.36B | B+ | ||
-0.16% | 48.45B | B+ | ||
-6.20% | 38.03B | A | ||
+0.91% | 35.61B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HOLX Stock
- Ratings Hologic, Inc.